Compare D R Horton Inc (DHI) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs 10X Genomics Inc — how do they compare? D R Horton Inc trades at $134.37 (market cap $37.99B), while 10X Genomics Inc trades at $82.37 (market cap $10.07B). The key difference: D R Horton Inc is far larger — about 3.8× 10X Genomics Inc's market cap, and D R Horton Inc pays a 1.33% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and 10X Genomics Inc for 92 Days on average.
| DHI | TXG | |
|---|---|---|
Market Cap | $37.99B | $10.07B |
Volume | 2,974,460 | 5,657,286 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $97.74 |
52-Week Low | $132.53 | $11.48 |
Typical Hold Time | 46 Days | 92 Days |
Enterprise Value | $43.09B | $9.59B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $133.28, down 2.54% on the day amid broader housing sector weakness. The stock shows bearish technical signals with oversold RSI conditions, while fundamentals remain solid with consistent earnings beats and attractive valuation multiples. Recent news highlights pressure from rising mortgage rates and housing market concerns, though the company maintains strong operational cash flow and analyst support.
DHI presents a value opportunity with below-market P/E of 12.95 and 47% analyst buy ratings, but faces headwinds from potential 9% mortgage rates and declining home sales. The consensus price target of $156.57 offers 17% upside, though investors should monitor Q3 2026 earnings on October 29 for margin sustainability.
TXG trades at $76.10, down 5.65% on the day, reflecting a bearish technical trend. The company reported revenue of $642.82M for 2025 with a net loss of $43.54M, though it has consistently beaten quarterly EPS estimates. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory. The stock faces resistance near $77 and support at $72.
The outlook is mixed; strong product demand and improving margins offer upside, but persistent losses and high valuation ratios pose risks. Analyst consensus is divided, with a $74.30 price target slightly below the current price, indicating cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
